Radiopharmaceutical leaders argued that the oncology sector is not fully leveraging the field’s dosing potential, citing a pattern of safety limitations that have constrained how often investigational radiopharmaceuticals can be administered. Louise Emmett and other experts describe how some developers have encountered unintended toxicity affecting kidneys, liver, or bone marrow as radiopharmaceutical activity has expanded over the past five years. At least one company has shut down, and other organizations have faced setbacks linked to safety headaches. The central thrust is that radiopharmaceuticals could be designed or used with more frequent dosing if safety management improves—turning a historical limitation into a development target. For industry stakeholders, the discussion underscores that clinical translation in radiopharma is increasingly defined by dose cadence and organ-sparing strategies, not just tumor response.